GPP
NVCR icon

Great Point Partners’s NovoCure NVCR Stock Holding History

Great Point Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-241,000
Closed -$17.7M – 48
2022
Q4 		$17.7M Buy
+241,000
New +$18.1M 3.46% 9

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Great Point Partners's NVCR Position: Q3 2018 in Review

Great Point Partners sold out of NovoCure (NVCR) in Q3 2018, closing a stake of 713,998 shares — an estimated $22.3M sold.

Great Point Partners first reported a position in NVCR in Q3 2017 and held it in 4 quarters. The position peaked at $22.3M in Q2 2018. 176 funds tracked by Wall St. Rank hold NVCR as of Q3 2018.

  • Great Point Partners reported no remaining NovoCure position as of Q3 2018 after selling out during the quarter.
  • Great Point Partners sold 713,998 NovoCure shares in Q3 2018, an estimated $22.3M.
  • Great Point Partners first reported a position in NovoCure in Q3 2017 and held it in 4 quarters.
  • Great Point Partners's NovoCure position peaked at $22.3M in Q2 2018.
  • 176 funds tracked by Wall St. Rank held NovoCure as of Q3 2018.

Based on Great Point Partners's 13F filing for Q3 2018, filed 14 Nov 2018.